The FDA have approved deutetrabenazine, the deuterated analog of tetrabenazine, for chorea associated with Huntington disease. This represents an example of perhaps the simplest bioisostere and the first example to gain FDA approval.

There are several other examples of the H to D change to reduce the rate of metabolism and improve pharmacokinetics.